Bridgepoint acquires HTL

Unquote understands that the GP invested via its Bridgepoint Europe V fund, which held a final close in March 2015 on €4bn, exceeding its €3.5bn target. 

Bridgepoint intends to support HTL's international expansion, especially in Asia and North America, and boost the company's external growth.

Naxicap acquired HTL in February 2017 from the founding family as part of a management buy-in. Following the deal, Naxicap appointed Yvon Bastard as CEO to lead the business.

Company
Established in 1992 and based in Fougères, HTL specialises in the manufacture and purification of hyaluronic acid and other biological polymers for the pharmaceutical and medical industries. It employs 110 staff.

People
Bridgepoint – Vincent-Gael Baudet (partner).
Naxicap Partners – Eric Aveillan (managing partner).
HTL – Yvon Bastard (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Buyouts
• Exits
• France
• Healthcare
• Bridgepoint
• Naxicap
• France
• Secondary buyout